Almac and TTP Labtech form alliance in fluorescence lifetime technology
January 7, 2013
Combining cutting edge science with first rate engineering
FLEXYTE™ assays harness the power and potential of fluorescence lifetime technology
Almac and TTP Labtech announced today the formation of an alliance in the field of fluorescence lifetime (FLT) technology to provide class leading screening performance. This will give customers of either party access to a broad range of biological applications coupled with the next generation of microplate reader technology.
FLT as a reading modality offers a robust, antibody-free, homogeneous assay platform which enables the user to avoid interference from fluorescent compounds within a screening library. Developed utilising experience in peptide engineering and chemical synthesis and design, Almac’s FLEXYTE™ assays harness the power and potential of FLT to provide an efficient and economical platform for screening and profiling. The evolving assay platform offers solutions for many major therapeutic target classes including kinases, proteases, phosphatases, DUB and an increasing number of epigenetic targets.
TTP Labtech’s Ameon™ system represents the next generation of FLT reader technology. By offering real-time decay curve analysis, the Ameon™ system provides a revolutionary combination of speed, precision, and data quality for FLT assays that can be readily integrated into HTS workflows.
‘The development of the Ameon™ reader by TTP Labtech has introduced an exciting new dimension to FLT technology and we are pleased that Almac’s FLEXYTE™ customers will be able to benefit from this advance in reader technology’ said Dr Stephen Barr, President and Managing Director of Almac Sciences.
‘We are excited by the potential of the FLEXYTE™ and Ameon™ reader combination to deliver robust, cost-effective screening results and enhanced productivity through better discrimination of lead compounds’ said Dr Wayne Bowen, Chief Scientific Officer of TTP Labtech.
Wayne Bowden from TTP Labtech tells SelectScience how this alliance will give customers access to a broad range of biological applications coupled with the next generation of microplate reader technology. Wayne also tells us more about TTP Labtech’s Ameon™ system, which represents the next generation of FLT reader technology. In addition Robert Grundy from Almac discusses how FLEXYTE™ assays harness the power and potential of FLT to provide an efficient and economical platform for screening and profiling. Click here to view
The Almac Group provides a broad range of services from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply and IXRS® technology (IVRS/IWRS), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors. The company employs over 3,300 individuals and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California.
About TTP Labtech Limited
Based near Cambridge, UK, TTP Labtech creates, designs and manufactures robust, reliable and easy-to-use instrumentation to offer life scientists better tools and techniques, simplifying complex operations, saving time and material costs.
We provide state-of-the-art solutions developed for specific product areas including: cell-based screening (acumen®, mirrorball®); sample management (comPOUND®), low liquid handling (mosquito®) and the management of analytical automation (lab2lab).
TTP Labtech is owned by its employees, and our continued drive to innovate combines cutting edge science with first rate engineering, manufacturing and outstanding customer support.
For further information please visit www.ttplabtech.com